Close Menu

Interpace Diagnostics

The revenue growth was primarily driven by the company's two thyroid tests, which have been steadily gaining payor coverage.

Interpace said that its two thyroid tests are now covered for over 280 million patients nationwide including Medicare, Medicare Advantage, and national and regional health plans.

The payor has agreed to cover Interpace's ThyGenX and ThyraMir, for thyroid nodules deemed indeterminate by standard cytopathological analysis.

Interpace can now offer the new service alone or in conjunction with ThyGenX next-generation sequencing oncogene panel in New York.

The company's ThyGenX and ThyraMir tests are designed for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

Alere this week informed the New York Stock Exchange in writing of its intention to voluntarily delist its Series B convertible perpetual preferred stock from the exchange.

The agreement, which covers Interpace's ThyGenX and ThyraMIR diagnostic tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

During the quarter, the firm secured payor coverage for its tests with UnitedHealthcare, Premera Blue Cross, and Aetna. 

Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.

Pages